Related Experiment Video
Updated: Jan 11, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
When Covering and Discovering Are at Odds: How the Logic of US Health Insurance Undercuts the Promise and Equity of
Emily Hammad Mrig1, Mark Schlesinger2, Jennifer M Weiss3
1University of California, San Francisco.
Context:
Despite precision medicine's promise to revolutionize health care, access remains uneven, and disparities persist. This study examines how conflicts between the institutional logics of genetic science ("discovering") and market-based health insurance ("covering") impede precision-driven health equity.
Methods:
The authors conducted 44 semistructured in-depth interviews with individuals at elevated risk for hereditary cancer. Data were analyzed using an abductive approach, combining thematic analysis with grounded theory tools.
Findings:
Analysis reveals seven "zones of conflict" where precision medicine's aspirations clash with insurance practices, creating barriers to genetic testing and related services. These zones span initial access barriers (e.g., complex billing, inconsistent guideline uptake) and downstream care factors (e.g., financial concerns, lack of retesting guidelines). The interplay between expanding genomic knowledge and the fragmented American health care system particularly disadvantages underrepresented and minority populations.
Conclusions:
Participant experiences reveal more unanticipated sources of inequity than precision medicine proponents anticipated. Incremental reforms targeting these conflict zones-such as guideline harmonization, expanding coverage mandates, and enhancing patient advocacy related to insurance coverage-could mitigate cascading disparities. This study highlights the importance of addressing institutional misalignments to realize the full equitable potential of precision medicine involving genetics.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Prevention
Some...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Targeted Cancer Therapies
There are several types of targeted therapies against...

